Plain-English translation of NCT04840797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a registry study that collects real-world information from people who have experienced sudden cardiac arrest and received treatment with the HeartStart HS1 defibrillator. The study aims to confirm that the HeartStart HS1 defibrillator is safe and performs as expected in actual use, particularly looking at how well it delivers the electrical shock needed to restart the heart.
After a medical device is approved and used in real patients, companies need to collect ongoing data to make sure it continues to work safely and effectively in everyday situations. This registry helps track what happens when the device is actually used in the community.
You likely qualify if…
You likely don't qualify if…
As a participant, your medical information and details about what happened during your cardiac arrest event and treatment will be collected and recorded in a database. You are not receiving any new treatment — the study simply gathers information about the defibrillator's performance after it has already been used to help you. The data collection typically happens once, after the emergency event.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States
Enrollment target
~1,400 participants
Started
February 2021
Primary completion
December 2030
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chase Wennick
Philips Healthcare
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.